title: [Diagnosis and treatment in acute stroke].
abstract: Recently, diagnosis and treatment for transient ischemic attack (TIA) and acute stroke is greatly changing in Japan. Now, TIA is closed up because it has been clarified that TIA attack is very high risk for following stroke. Therefore, TIA patients should be immediately evaluated TIA etiology and be treated after TIA attack as soon as possible in order to prevent following stroke. Medical equipment for stroke such as ultrasound and MRI is improving. In particular, development of MRI study including DWI, T(2)(*), FLAIR, and MRA resulted in accurate diagnosis and etiology of super acute ischemic stroke, and paradoxical embolism, arterial dissection, and aortogenic embolism can be diagnosed in acute stroke patients. t-PA therapy has been approved by Japanese government since 1995, October. t-PA therapy can improve patient outcome due to early recanalization of occluded brain artery. The early recanalization rate was approximately 50% of major artery occlusion. We reported that early recanalization depended on time from stroke onset to IV-t-PA administration. Furthermore, we shown that the large ischemic lesions on diffusion-weighted imaging done before-PA infusion and presence of M1 susceptibility vessel sign were predictor for no-early recanalization and poor outcome. Stroke unit consisting stroke doctors, stroke nurse, and rehabilitation staff can improve patient outcome. In this way, management for acute stroke is greatly changing in Japan.
authors.affiliation: Department of Stroke Medicine, Kawasaki Medical School.
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kimura
mesh_terms: D015415:Biomarkers / Q000097:blood; D057510:Endovascular Procedures; D006801:Humans; D002546:Ischemic Attack, Transient; D008279:Magnetic Resonance Imaging; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010348:Patient Care Team; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain; D010959:Tissue Plasminogen Activator